Invention Grant
- Patent Title: Crystalline forms of tyrosine kinase inhibitors and their salts
-
Application No.: US14772264Application Date: 2014-03-14
-
Publication No.: US09718794B2Publication Date: 2017-08-01
- Inventor: Jay Jie-Qiang Wu , Ling Wang
- Applicant: Purdue Pharma L.P.
- Applicant Address: US CT Stamford
- Assignee: Purdue Pharma L.P.
- Current Assignee: Purdue Pharma L.P.
- Current Assignee Address: US CT Stamford
- Agency: Sterne, Kessler, Goldstein & Fox P.L.L.C.
- International Application: PCT/US2014/027591 WO 20140314
- International Announcement: WO2014/152663 WO 20140925
- Main IPC: C07D261/20
- IPC: C07D261/20 ; A61K31/496
Abstract:
The invention relates to various polymorphic forms and amorphous form of sodium 4-((3-(4-cyclohexylpiperazin-1-yl)-6-oxo-6H-anthra[1,9-cd]isoxazol-5-yl)amino)benzate, including the polymorphic form A, mixtures of the polymorphs, process for the preparation thereof and the use thereof in a pharmaceutical composition containing thereof.
Public/Granted literature
- US20170001969A9 CRYSTALLINE FORMS OF TYROSINE KINASE INHIBITORS AND THEIR SALTS Public/Granted day:2017-01-05
Information query
